Inmed pharmaceuticals increases cannabinoid yield to 5 g/l with integrasyn™ in advance of commercial scale production

Vancouver, british columbia, june 17, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that its continued optimization of integrasyn™ has increased the cannabinoid yield to a level of 5 g/l, further improving the economics of this proprietary manufacturing approach in advance of large-scale production.
INM Ratings Summary
INM Quant Ranking